Impel NeuroPharma to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022
March 17, 2022 16:01 ET
|
Impel NeuroPharma
SEATTLE, March 17, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with...
Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree
March 17, 2022 08:00 ET
|
Impel NeuroPharma
-Transaction Provides Immediate, Non-Dilutive Capital to Further Support Commercialization of Trudhesa™ -$100 million in gross proceeds to be funded at close, extending estimated corporate cash...
Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences
February 28, 2022 08:00 ET
|
Impel NeuroPharma
SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with...
Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights
January 18, 2022 08:05 ET
|
Impel NeuroPharma
Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company’s Guidance Range Achieved Broad and Favorable...
Impel NeuroPharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 15, 2021 08:00 ET
|
Impel NeuroPharma
Launched Trudhesa™ (dihydroergotamine mesylate) Nasal Spray (0.725 mg per spray) for the Acute Treatment of Migraine with and without Aura in Adults Mobilized 60-Person Salesforce with a Targeted...
Impel NeuroPharma to Present at the Guggenheim Securities 3rd Annual Neuro/Immunology Conference
November 09, 2021 08:00 ET
|
Impel NeuroPharma
SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases...
Impel NeuroPharma to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021
November 08, 2021 08:00 ET
|
Impel NeuroPharma
SEATTLE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases...
Impel NeuroPharma Announces Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for the Acute Treatment of Migraine
September 28, 2021 08:30 ET
|
Impel NeuroPharma
Trudhesa is the First and Only Therapeutic to Use POD® Technology to Deliver Dihydroergotamine Mesylate (DHE)—a Proven, Well-Established Therapeutic—to the Vascular-Rich Upper Nasal Space ...
Impel NeuroPharma Announces Pricing of $45.0 Million Public Offering
September 09, 2021 20:00 ET
|
Impel NeuroPharma
SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from...
Impel NeuroPharma Announces Launch of Proposed Public Offering
September 07, 2021 16:01 ET
|
Impel NeuroPharma
SEATTLE, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from...